Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT syndromes, atrial fibrillation and oncology. Central to Thryv’s approach is the use of SGK1 inhibitors - SGK1 is a protein kinase which regulates a number of ion currents in human cardiac cells and supports cell survival and proliferation in many resistant cancer cells. Thryv has rapidly advanced their portfolio of SGK1 inhibitors and have completed a Phase 1 healthy volunteer study for LQT-1213.

Thryv Therapeutics

Founded: 2019
Location: Montreal, QC
Employee range: 1-50
Clinical stage: Clin2
Therapy area: Drug induced long QT syndrome
Drug types: CVV, GEN, ONC
Lead product: Islatertib
Funding: 10-100M

Drug notes:

About:

Jobs: